Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25179049 | 0.80 | KIF11 (0.35) | KIF11 | |
| SCHEMBL407346 | 0.78 | GPR3 (0.41) | GPR3KIF11CES1NPC1RAB9A | |
| SCHEMBL622940 | 0.78 | GPR3 (0.41) | GPR3NOTUMKIF11CES1NPC1 | |
| SCHEMBL538958 | 0.76 | GPR3 (0.41) | GPR3KIF11CES1NPC1RAB9A | |
| SCHEMBL401985 | 0.76 | KMT2A (0.36) | NPC1RAB9ALMNAGAAPKM | |
| SCHEMBL1066922 | 0.76 | GPR3 (0.40) | GPR3NOTUMKIF11CES1NPC1 | |
| SCHEMBL457747 | 0.76 | GPR3 (0.40) | GPR3KIF11CES1NPC1RAB9A | |
| SCHEMBL3076523 | 0.76 | GPR3 (0.40) | GPR3NOTUMKIF11CES1NPC1 | |
| SCHEMBL1008548 | 0.76 | ALDH1A1 (0.43) | GPR3CYP2C9USP2LMNACYP1A2 | |
| SCHEMBL8128913 | 0.75 | DHODH (0.39) | GPR3NOTUMCYP2C9SCN5AP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | claimed |
| EP-4223753-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-08-09 | — | — | EP | claimed |
| CN-116234550-A | Aromatic formyl substituted tricyclic compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-06-06 | — | — | CN | claimed |
| WO-2023028341-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | claimed |
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| US-20040116428-A1 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004048320-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2004-06-10 | — | — | WO | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| EP-0511845-B1 | Pesticidal 1-aryl-5-(substituted alkylideneimino)-pyrazoles | AVENTIS CROPSCIENCE SA (FR) | 2001-10-31 | — | — | EP | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| US-5556873-A | AGRICULTURAL PESTICIDES | RHONE-POULENC INC. (US) | 1996-09-17 | — | — | US | claimed |
| US-5321040-A | Pesticidal 1-aryl-5-(substituted N-cinnamylideneimino) pyrazoles | RHONE-POULENC INC. (US) | 1994-06-14 | — | — | US | claimed |
| US-5236938-A | Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles | RHONE-POULENC INC. (US) | 1993-08-17 | — | — | US | claimed |
| EP-0511845-A1 | Pesticidal 1-aryl-5-(substituted alkylideneimino)-pyrazoles | RHONE-POULENC AGROCHIMIE (FR) | 1992-11-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | GPR3 1552/4885NOTUM 3018/4885KIF11 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.